###begin article-title 0
###xml 43 48 43 44 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
The Possible Role of Tumor Necrosis Factor-alpha in Diabetic Polyneuropathy
###end article-title 0
###begin p 1
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 91 96 91 92 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 102 107 98 99 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 236 241 228 229 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 535 540 523 524 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 751 756 735 736 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
In this review, the authors provide evidences that imply the role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of diabetic complications, especially diabetic polyneuropathy. Under chronic hyperglycemia, endogenous TNF-alpha production is accelerated in microvascular and neural tissues, which may undergo an increased microvascular permeability, hypercoagulability, and nerve damage, thus initiating and promoting the development of characteristic lesions of diabetic microangiopathy and polyneuropathy. Enhanced TNF-alpha production may also promote atherosclerosis due to increased insulin resistance and the expression of adhesion molecules. Clinical application of specific agents that suppress production and/or activity of TNF-alpha may inhibit the development and exacerbation of chronic diabetic complications.
###end p 2

